TRexBio
PublicTRexBio is now publicly traded
The data on this page reflects TRexBio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Extension
Jan 27, 2026
Total Funding Raised
$219M
Company Overview
TRexBio operates in Biotech and is based in South San Francisco, California. It has raised $219M.
TRexBio is a biotechnology company that develops immunoregulatory medicines by mapping human tissue regulatory T cell behavior to disease processes to identify novel therapeutic targets.
Sector
Biotech
Verticals
Life Sciences
AI Layer
Application
TRexBio Comparables
Compare TRexBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mozart Therapeutics | 84% | |
| Sonoma Biotherapeutics | 80% | |
| Egle Therapeutics | 80% |
For institutional investors. Book with your work email.
TRexBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jan 27, 2026 | ||||
| Series B | Nov 13, 2024 | ||||
| Series A Extension | Mar 8, 2022 | ||||
| Series A | Jun 22, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
TRexBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Avego Management | Series B, Series B Extension |
| Janus Henderson Group | Series B Extension |
| Agent Capital | Series B |
| Balyasny Asset Management L.P. | Series B Extension |
| SV Health Investors | Series B, Series A, Series A Extension, Series B Extension, Seed |
| Alexandria Venture Investments | Series B, Series A, Series A Extension, Series B Extension |
| Pfizer Ventures | Series B, Series A, Series A Extension, Series B Extension |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingOct 9, 2026
TRex Bio, Inc. receives $220M in venture financing to date, including a $50M raise in 2026 to support its ongoing Phase 1 trial.
- receives_financingOct 9, 2026
TRex Bio, Inc. receives $117M in IPO financing on its debut in California, pricing below the midpoint of its expected range.
- receives_financingSep 21, 2026
California-based TRex Bio, Inc. receives a $59M Series A in 2021 to advance its Treg-modulating biotech platform.
- goes_publicSep 18, 2026
TRex Bio, Inc. files paperwork for a U.S. initial public offering in United States on Sep 18th '26, adding to the fall biotech IPO pipeline.
For institutional investors. Book with your work email.
TRexBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.